Related Experiment Video
Updated: Aug 20, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Removing meperidine from the health-system formulary--frequently asked questions
M Christina Beckwith1, Erin R Fox, Jane Chandramouli
1University Hospitals and Clinics, and College of Pharmacy, University of Utah, Salt Lake City 84132, USA. Christina.beckwiths@hsc.utah.edu
Abstract:
Meperidine is FDA-approved for relieving moderate to severe pain and has been widely used since its introduction in the 1930s. However, the drug is no longer considered a first-line analgesic. Many clinicians recommend that meperidine be removed from health-systems or that its use be restricted, due to concerns about adverse reactions, drug interactions, and normeperidine neurotoxicity. In addition, clinical evidence shows that meperidine has no advantage over other opioids for biliary colic or pancreatitis. The formulary status of meperidine has been extensively discussed at University of Utah Hospitals and Clinics. The Pharmacy and Therapeutics Committee has been working with hospital staff to assess the impact of either removing meperidine from the formulary, or limiting its use. The Drug Information Service developed this document to help pharmacists respond to prescribers' questions and to alleviate the prescribers' concerns about these changes. Information is provided comparing meperidine with other opioids, including dosage equivalency, pharmacodynamics, pharmacokinetics, cost, adverse effects, and drug interactions. Where available, alternatives to meperidine are suggested for various indications.
Insights
Meperidine is not recommended as a first-line pain reliever due to safety concerns and lack of efficacy. This analysis guides clinicians on restricting its use and considering safer alternatives.
Area of Science:
- Pharmacology
- Clinical Pharmacy
Background:
- Meperidine, an opioid analgesic approved for moderate to severe pain, has been used since the 1930s.
- Current clinical practice suggests restricting or removing meperidine from formularies due to safety concerns.
Purpose of the Study:
- To evaluate the formulary status of meperidine.
- To provide evidence-based information for pharmacists and prescribers regarding meperidine's use and alternatives.
Main Methods:
- Review of clinical evidence on meperidine's efficacy and safety.
- Comparison of meperidine with other opioids regarding pharmacodynamics, pharmacokinetics, cost, and adverse effects.
- Identification of alternative analgesics for various indications.
Main Results:
- Meperidine is associated with adverse reactions, drug interactions, and normeperidine neurotoxicity.
- Clinical evidence does not support meperidine's superiority over other opioids for biliary colic or pancreatitis.
- Information on dosage equivalency, pharmacodynamics, pharmacokinetics, and cost is provided for comparison.
Conclusions:
- Meperidine is no longer considered a first-line analgesic.
- Restricting meperidine use and considering alternatives is recommended.
- This document aids healthcare professionals in managing meperidine-related prescribing decisions.
More Related Videos
Related Concept Videos
Enhanced Elimination of Poison
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

